IP Patents / Trademarks

Intellectual property is an important part of Paradigm’s strategic development and ownership of its repurposing programmes. Paradigm employs a multi-pronged approach, garnering protection from: exclusive supply agreements and partnerships; patents; and trademarks. We work closely with FB Rice in the development, registration and prosecution of our patents in order to secure a strong IP position.  Paradigm has registered trademarks for the BME product, ZILOSUL® and respiratory product RHINOSUL® for Allergic Rhinitis.

Patents & Patent Applications

Paradigm Biopharmaceuticals Ltd continues to pursue 4 main patent families in the areas of: bone marrow edema (BME); mucopolysaccharidoses (MPS);  alphaviral arthritis; and respiratory disease, including allergic rhinitis, asthma and chronic obstructive pulmonary disease (COPD). Paradigm has also acquired a patent application in the heart failure family.

Paradigm’s patent coverage includes:


In January 2018, Paradigm Biopharmaceuticals Ltd announced that it had been granted a European patent for the treatment of Bone Marrow Edema Lesions with Pentosan Polysulfate Sodium (PPS), and throughout 2018 has validated the patent in European member states. The European registration enhances Paradigm’s already strong patent position, adding to previously granted registrations in Australia, the United States, Japan, China, Canada, Taiwan, Singapore and other countries across the Asia-Pacific.

Mucopolysaccharidoses (MPS)

In November 2018, Paradigm Biopharmaceuticals Ltd announced its exclusive In-Licence Agreement for the use of iPPS in the treatment of mucopolysaccharidoses (MPS), a group of inherited lysosomal storage disorders. The Licensing Agreement and accompanying Phase 2a human data is a valuable addition to Paradigm’s product pipelines and IP portfolio. Granted patents cover key regions such as USA, Japan, Europe, Australia and New Zealand.


In September 2016, Paradigm Biopharmaceuticals Ltd announced a collaborative partnership with the Institute for Glycomics at Griffith University, whereby Paradigm was granted exclusive world-wide rights to commercialise a patent covering the use of PPS to treat alphavirus arthritis and joint pain.

Respiratory Disease

Paradigm Biopharmaceuticals Ltd has acquired patents over the use of PPS as a new treatment for respiratory diseases including Allergic Rhinitis (AR), Allergic Asthma (AA) and Chronic Obstructive Pulmonary Disease (COPS). Paradigm has registered patents in major markets including Australia, Canada, Europe, New Zealand, and The People’s Republic of China.

Further information on Paradigm’s Patent and IP position can be found in our ASX announcements and Annual Reports.


Paradigm Biopharmaceuticals Ltd has Trademarked its proprietary formulations of Pentosan Polysulfate Sodium for treatment of bone marrow edema (Zilosul®) and Allergic Rhinitis (Rhinosul®).